Tissue microarray as a research tool to study non-neoplastic liver diseases

Abdel‐Rahman, Mohamed H.; Agour, Ahmad A.; El-Azab, Dina S

doi:10.1097/01.elx.0000451425.36015.99

Cited by 9 publications

(5 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…IHC was carried out for all tumors except the ICC on 2mm diameter tissue microarrays (TMA) according to our previously published protocol[24]. At least two representative cores from each tumor and one core from matching non-tumor tissue were included.…”

Section: Methodsmentioning

confidence: 99%

Nuclear BAP1 loss is common in intrahepatic cholangiocarcinoma and a subtype of hepatocellular carcinoma but rare in pancreatic ductal adenocarcinoma

et al. 2018

View full text Add to dashboard Cite

Deletion in the 3p21 region, the chromosomal location of BAP1, has been reported in a subset of hepatocellular carcinoma (HCC), biliary and pancreatic cancers. This suggests that BAP1 could play a role in the pathogenesis of these tumors. We assessed the frequency of BAP1 loss by immunohistochemistry in 103 hepatic, biliary and pancreatic cancers. We also assessed chromosomal alterations in the BAP1 region in the same tumors by genotyping. We identified high frequency 4/8 (50%) of BAP1 loss in intrahepatic cholangicarcinoma (ICC). However the frequency was lower in HCC 9/51 (17.6%), pancreatic 1/42(2.4%) and extrahepatic biliary cancers (0/2). Loss of heterozygosity of at least one marker from the 3p21 region was observed in 75% of ICC, 52.9% of HCC and 45.2% of pancreatic cancers. Expression of hepatocytic (HepPar1) and bile duct (cytokeratin 7) markers were common (7/9, 77.8%) in the HCC tumors with loss or decrease of BAP1 compared with those with preserved BAP1 (18/42, 42.9%), (Fisher exact p = 0.0751). Our results confirm the high frequency of BAP1 alterations in ICC and low frequency in pancreatic cancers. It also suggests that BAP1 is commonly altered in a subtype of HCC with both hepatocytic and biliary differentiation. Further studies of the therapeutic implications of our findings are warranted.

show abstract

Section: Methodsmentioning

confidence: 99%

Nuclear BAP1 loss is common in intrahepatic cholangiocarcinoma and a subtype of hepatocellular carcinoma but rare in pancreatic ductal adenocarcinoma

et al. 2018

View full text Add to dashboard Cite

show abstract

“…The retrieved tissue cores were arrayed onto a recipient block. A map is created to show the origin and location of each core ( 28 ).…”

Section: Methodsmentioning

confidence: 99%

Role of CTLA4 and pSTAT3 Immunostaining in Colorectal Carcinoma Prognosis and Treatment

Allam,

Kasem,

Hegazy

et al. 2024

Iran J Pathol

View full text Add to dashboard Cite

“…The tissue microarray technique was done for both tumour and non-tumour tissue samples [ 24 ]. For the normal liver tissue, sections from needle liver biopsy samples were used.…”

Section: Exclusion Criteriamentioning

confidence: 99%

The expression of VEGF and cyclin D1/EGFR in common primary liver carcinomas in Egypt: an immunohistochemical study

Sweed,

El Gammal,

Kilany

et al. 2023

ecancer Journal

View full text Add to dashboard Cite

Background: The most common types of primary malignant liver tumours are hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA). Treatment options for patients who are inoperable/advanced, or recurring are challenging. Cyclin D1, epidermal growth factor (EGFR) and vascular endothelial growth factor (VEGR) are common carcinogenic proteins that have potential therapeutic targets in various cancers. They have been implicated in the development of HCC and CCA. In this study, we aimed to evaluate the oncogenic function expression of cyclin D1, EGFR and VEGF in HCC and CCA of Egyptian patients. This could help to validate their therapeutic potential. Material and methods: Tumour cases were selected from 82 cases of primary liver carcinomas, with 58 cases being from HCC and 24 cases from CCA compared to 51 non-tumour adjacent liver cases and 18 from normal liver tissue. The immunohistochemical study of cyclin D1, EGFR and VEGR was conducted. Results: Cyclin D1, EGFR and VEGF are overexpressed in HCC and CCA as compared to the control group ( p < 0.001). Cyclin D1 was related to well-differentiated grade and early pathologic stage in HCC ( p = 0.016 and p = 0.042, respectively). The well-differentiated grade showed significantly higher VEGF levels ( p = 0.04). In the CCA group, however, EGFR was strongly related to high tumour size ( p = 0.047). EGFR and VEGF were overexpressed in HCC raised in the non-cirrhotic liver compared to those developed in post-hepatitic liver cirrhosis ( p = 0.003 and p = 0.014). Conclusion: Cyclin D1, EGFR and VEGF shared significant overexpression in HCC and CCA. EGFR and VEGF may play an oncogenic function in the development of HCC in non-cirrhotic liver. Furthermore, cyclin D1 and VEGF may play a good prognostic function in HCC, but EGFR may play a bad prognostic role in CCA.

show abstract

Tissue microarray as a research tool to study non-neoplastic liver diseases

Cited by 9 publications

References 12 publications

Nuclear BAP1 loss is common in intrahepatic cholangiocarcinoma and a subtype of hepatocellular carcinoma but rare in pancreatic ductal adenocarcinoma

Nuclear BAP1 loss is common in intrahepatic cholangiocarcinoma and a subtype of hepatocellular carcinoma but rare in pancreatic ductal adenocarcinoma

Role of CTLA4 and pSTAT3 Immunostaining in Colorectal Carcinoma Prognosis and Treatment

The expression of VEGF and cyclin D1/EGFR in common primary liver carcinomas in Egypt: an immunohistochemical study

Contact Info

Product

Resources

About